Don Walkinshaw
About Don Walkinshaw
Don Walkinshaw is a Senior Director of Consulting at Shift Health, where he has worked since 2012. He has a strong background in health science, having held various research and development positions in academia and industry, and has contributed significantly to life sciences research funding.
Work at Shift Health
Don Walkinshaw has been serving as the Senior Director of Consulting at Shift Health since 2012. In this role, he has contributed to the development and implementation of consulting strategies that support clients in the biopharmaceutical sector. His work involves collaborating with clients across various regions, including Canada, the US, Latin America, Europe, the Middle East, and Asia. He focuses on innovative research and development, business development, and commercial strategies tailored to the needs of health research organizations.
Education and Expertise
Don Walkinshaw holds a PhD in Experimental Medicine from McGill University, where he studied from 2006 to 2011. He also earned a Master of Science in Kinesiology & Health Science and a Bachelor of Science Special Honours in Kinesiology & Health Science, both from York University. His educational background equips him with a strong foundation in health sciences, which he applies in his current consulting role and previous research positions.
Background
Prior to his current position, Don Walkinshaw worked as a Research Scientist at the Goodman Cancer Research Centre at McGill University from 2006 to 2011. He also held a Postdoctoral Research Fellow position at the University Health Network for six months in 2011-2012. Additionally, he gained experience as a Business Development Intern at Tornado Medical Systems in 2012 and as a Graduate Student Assistant at York University from 2004 to 2006.
Achievements
Don Walkinshaw has received a Banting and Best Canada Graduate Scholarship from the Canadian Institutes of Health Research for his research on novel signal transduction pathways in cancer. He has raised over $100 million for life sciences research, impacting various disease areas such as oncology, infectious diseases, brain disorders, and cardiovascular and metabolic disorders. His research includes investigating novel drug combination therapies for leukemia during his postdoctoral fellowship at the Princess Margaret Cancer Centre.